Yearly Archives: 2020


Researchers grow first plant-based gel to help organoid development for biomedical applications – Microbioz India

Monash University researchers have created the worlds first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of studies into cancer and COVID-19.

This discovery by researchers at BioPRIA (Bioresource Processing Institute of Australia), Monash Universitys Department of Chemical Engineering and the Monash Biomedicine Discovery Institute will develop organoids cheaper, faster and more ethically.

The hydrogel can also improve drug screening and disease modelling for infectious diseases, like COVID-19; metabolic diseases, such as obesity and diabetes; and cancer.

The findings, published inAdvanced Science, emerge as a promising finding for growth of organoids for essential laboratory testing across the world. With additional testing, this hydrogel could be available to researchers and health professionals across the world in less than 12 months.

Nanocellulose gels cost just cents for every 10ml used, compared to $600 or more for the current gold standard.

Above all, nanocellulose gels are completely plant-based, preventing the harvesting of animal organs and unknown biomolecules for any advanced medical testing.

Professor Gil Garnier and Dr Rodrigo Curvello from BioPRIA within Monash Universitys Department of Chemical Engineering led the study.

Organoids provide a robust model for key applications in biomedicine, including drug screening and disease modelling. But current approaches remain expensive, biochemically variable and undefined.

Gil Garnier, Director of BioPRIA, Monash University

These are major obstacles for fundamental research studies and the translation of organoids to clinics. Alternative matrices able to sustain organoid systems are required to reduce costs drastically and to eliminate the unreliability of unknown biomolecules.

As nanocellulose hydrogel is animal-free, its composition is controlled perfectly and reproducible unlike the current progress and fully mimic the human body conditions.

Organoids are three-dimensional, miniaturised and simplified versions of organs produced in vitro that can replicate behaviours and functionalities of developed organs.

Commonly referred to as organs in a dish or mini-organs, organoids are an excellent tool to study basic biological processes. Through organoids, we can understand how cells interact in an organ, how diseases affect them and the effects of drugs in disease reduction.

Organoids are generated from embryonic, adult, pluripotent orinduced pluripotent stem cells, as well as from primary healthy or cancerous tissues.

For long-term use, organoids are commonly embedded within an Engelbreth-Holm Swarm (EHS) matrix derived from the reconstituted basement membrane of mouse sarcoma.

Currently, organoid culture is dependent of this expensive and undefined tumour-derived material that hinders its application in high-throughput screening, regenerative medicine and diagnostics.

Our study was essentially able to use an engineered plant-based nanocellulose hydrogel that can replicate the growth of small intestinal organoids derived from mice, Dr Curvello said.

It is essentially made from 99.9% water and only 0.1% solids, functionalised with a single cell adhesive peptide. Cellulose nanofibers are linked with salts that provide the microenvironment needed for small intestinal organoid growth and proliferation.

Engineered nanocellulose gel represents a sustainable alternative for the growth of organoids, contributing to reducing the costs of studies on diseases of global concern, particularly in developing countries.

Source:

Journal reference:

Curvello, R.,et al.(2020) Engineered PlantBased Nanocellulose Hydrogel for Small Intestinal Organoid Growth.Advanced Science.doi.org/10.1002/advs.202002135.

Go here to see the original:
Researchers grow first plant-based gel to help organoid development for biomedical applications - Microbioz India

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

East Setauket, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT)(“Lixte” or the “Company”), today announced the pricing of its underwritten public offering of 1,200,000 units of securities at an offering price of $4.75 per unit. Each unit is immediately separable into one share of common stock and one warrant to purchase one share of common stock and will be issued separately. The warrants underlying the units are immediately exercisable for one share of common stock at an exercise price of $5.70 and expire 5 years from the date of issuance.

Continued here:
Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 and host investor meetings.

See the rest here:
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.

Read the rest here:
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, will participate in a fireside chat hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM EST.

Excerpt from:
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference

Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

Original post:
Cronos Group Inc. to Speak at the Cowen 2020 Boston Cannabis Conference

Novavax to Participate in Upcoming Conferences

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.

Read more:
Novavax to Participate in Upcoming Conferences

Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

See the original post here:
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference